News and Trends 14 Apr 2021
DBV Battles Aimmune for Share of Peanut Allergy Treatment Market
Last year, the FDA rejected DBV Technologies’ peanut allergy treatment and approved that of its rival Aimmune. After recent talks with the FDA and EMA, DBV has laid out a comeback plan that could carve it a niche in the peanut allergy treatment market. The French biotech firm DBV is coming back from a snub by […]